G. Preston

Sunitinib-associated thrombotic microangiopathy: a significant risk.

D. Adamson, D. Meiklejohn, F. Buckley, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study

D. Werring, L. Zambreanu, A. Coles, 2021, The Lancet.

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

A. Schuh, D. Cairns, S. Paneesha, 2021, Blood.

A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO‐idel)

H. Ramroth, C. Fegan, T. Nicholson, 2021, British journal of haematology.

Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials

J. Tighe, K. Thein, Thura Win Htut, 2020, EJHaem.

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.

P. McKay, J. Khwaja, N. Martínez-Calle, 2020, Blood advances.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

A. Schuh, D. Cairns, J. Shingles, 2023, The Lancet. Oncology.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

L. Duley, S. Paneesha, O. Sheehy, 2023, The New England journal of medicine.

Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study

A. Schuh, N. Martínez-Calle, T. Eyre, 2023, British journal of haematology.